LB-100 is under clinical development by Lixte Biotechnology Holdings and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect LB-100’s likelihood of approval (LoA) and phase transition for Recurrent Glioblastoma Multiforme (GBM) took place on 05 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their LB-100 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

LB-100 overview

LB-100 is under development for the treatment of solid tumors including colon cancer, pancreatic cancer, breast cancer, ovarian cancer, carcinoid tumor, testicular cancer, duodenal cancer, non-small cell lung cancer, thymoma, soft tissue sarcoma, recurrent glioblastoma multiforme, imatinib-resistant chronic myelogenous leukemia, hepatocellular carcinoma (HCC), acute ischemia of brain, septic shock, depression, myocardial ischemia, del5q myelodysplastic syndrome, pheochromocytoma, sarcoma, advanced/metastatic soft tissue sarcoma (undifferentiated pleomorphic sarcoma, leiomyosarcoma, myxoid and hypercellular myxoid liposarcoma, myxofibrosarcoma, NOS sarcoma, synovial sarcoma, fibrosarcoma, or malignant nerve sheath tumor) and melanoma, post-traumatic stress disorder (PTSD),type 2 diabetes, obesity, insulin resistance, small cell lung cancer, Angelman syndrome, triple negative breast cancer and achondroplasia (ACH). LB-100 is a synthetic derivative of cantharadin. The drug candidate is administered through intravenous route and oral route. It acts by targeting PP2A. It was also under development for the treatment of insulin resistance.

Lixte Biotechnology Holdings overview

Lixte Biotechnology Holdings (Lixte) is a drug discovery company, which focuses on the discovery and development of novel drugs for the treatment of cancer and non-cancer diseases using its biomarker technology. It develops two classes of drugs, namely, protein phosphatase inhibitors (PTase-i) designated as the LB-100 series; and histone deacetylase inhibitors (HDACi), designated as the LB-200 series of compounds. The company’s product pipeline comprises drug candidates for the treatment of cancer and neurodegenerative disorders such as small lung cancer, soft tissue sarcoma, myelodysplastic syndrome, and glimos, among others. Lixte primarly operates in the US and has collaborations with academic centers, contract research organizations and pharmaceutical companies for development of its anti-cancer treatments. Lixte is headquartered in New York, the US.

Quick View LB-100 LOA Data

Report Segments
  • Innovator
Drug Name
  • LB-100
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Genetic Disorders
  • Metabolic Disorders
  • Musculoskeletal Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.